Venous thromboembolism in transgender and gender non-binary youth is rare and occurs in the setting of secondary risk factors: A retrospective cohort study (Q29775)

No description defined

Venous thromboembolism in transgender and gender non-binary youth is rare and occurs in the setting of secondary risk factors: A retrospective cohort study.

Language	Label	Description	Also known as
English	Venous thromboembolism in transgender and gender non-binary youth is rare and occurs in the setting of secondary risk factors: A retrospective cohort study	No description defined	Venous thromboembolism in transgender and gender non-binary youth is rare and occurs in the setting of secondary risk factors: A retrospective cohort study.

Statements

1 reference

Venous thromboembolism in transgender and gender non-binary youth is rare and occurs in the setting of secondary risk factors: A retrospective cohort study. (English)

1 reference

stated in

PubMed

abstract

The risk of venous thromboembolism (VTE) with gender-affirming hormone therapy (GAHT) in transgender and gender non-binary (TNB) youth is unclear. (English)

source label

BACKGROUND (English)

subsection NLM category

1

2024

1 reference

To identify the rate of VTE in a cohort of TNB youth followed in the transgender health clinic at Boston Children's Hospital, and to investigate the impact of congenital thrombophilia diagnosis on the use of GAHT. (English)

source label

OBJECTIVE (English)

subsection NLM category

2

2024

1 reference

ICD-9 and ICD-10 codes were used to identify eligible individuals, defined as (i) having a diagnosis of gender dysphoria and (ii) venous thromboembolism (VTE). (English)

source label

METHODS (English)

subsection NLM category

3

2024

1 reference

Data were abstracted from a review of medical records. (English)

source label

METHODS (English)

subsection NLM category

4

2024

1 reference

A second data query assessed TNB individuals who had an associated thrombophilia diagnosis. (English)

source label

METHODS (English)

subsection NLM category

5

2024

1 reference

The primary analysis included 1860 individuals. (English)

source label

RESULTS (English)

subsection NLM category

6

2024

1 reference

Total 942 individuals (50.6%) had started GAHT at the time of data analysis. (English)

source label

RESULTS (English)

subsection NLM category

7

2024

1 reference

Mean age (±SD) at GAHT initiation was 16.8 (±1.9) years. (English)

source label

RESULTS (English)

subsection NLM category

8

2024

1 reference

Five thrombotic events were identified in three (0.13%) individuals, all in the setting of additional VTE risk factors. (English)

source label

RESULTS (English)

subsection NLM category

9

2024

1 reference

Only two of five thrombotic events occurred while receiving GAHT. (English)

source label

RESULTS (English)

subsection NLM category

10

2024

1 reference

The rate of VTE in the GAHT cohort did not statistically differ from the rate of VTE in the non-GAHT cohort (0.1% vs. 0.2%, p = .62). (English)

source label

RESULTS (English)

subsection NLM category

11

2024

1 reference

Of the 10 individuals diagnosed with a congenital thrombophilia, two transmasculine individuals received prophylactic anticoagulation prior to GAHT. (English)

source label

RESULTS (English)

subsection NLM category

12

2024

1 reference